Immune modulator N-803 does not control HIV rebound, suggesting a combination approach is needed for a functional cure
New antiretrovirals in the pipeline could be part of twice-yearly HIV treatment
African paediatric studies at CROI: HIV remission in children, three bnAbs in babies, two years on injectables in teens
Broadly neutralising antibody plus cabotegravir maintains viral suppression for at least a year
Half the participants from placebo arm of HIV cure trial have prolonged viral load remission when given broadly neutralising antibodies
Doravirine/islatravir non-inferior to Biktarvy as first-line treatment
Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens
CD8 cell fitness predicts who benefits most from antibody-based cure strategies
Antibody from Tanzanian woman suppresses almost all tested HIV variants including resistant viruses in pre-clinical study
